Mega CapHealthcareDividend

AMGN — Amgen Inc.

Biotechnology · Founded 1980 · Thousand Oaks, California · CEO: Robert Bradway

Amgen is one of the world's largest biotechnology companies, pioneering the use of recombinant DNA technology to develop medicines for serious illnesses. Its portfolio spans oncology (Blincyto, Lumakras), cardiovascular (Repatha), bone health (Prolia, XGEVA), and inflammatory diseases (Otezla, Enbrel). Amgen has been expanding into biosimilars and acquired Horizon Therapeutics in 2023 to add rare disease therapies. The company generates among the highest profit margins in the pharmaceutical industry.

How Amgen Inc. Makes Money

Biologic drug sales across oncology, inflammation, bone health, and cardiovascular disease

Biosimilar revenues from approved biosimilar versions of other companies' reference biologics

Royalties on licensed technologies and collaboration revenues

Horizon Therapeutics rare disease product revenues including Tepezza (thyroid eye disease)

Key Metrics Investors Watch

Volume and net selling price growth for key products (Repatha, Prolia, Otezla)
Biosimilar market share gains vs. reference product erosion
Pipeline advancement in obesity (MariTide), oncology, and rare disease
Return on invested capital given high R&D and acquisition spending
Free cash flow generation and leverage from Horizon acquisition

Competitive Advantages

Pioneer in large-molecule biologics manufacturing with decades of quality and safety track record
Repatha is a leading PCSK9 inhibitor for cholesterol reduction with growing cardiovascular market
Biosimilars platform diversifies revenue and leverages manufacturing expertise
MariTide obesity molecule positions Amgen as a potential competitor to GLP-1 drugs from Novo/Eli Lilly

Key Risks

Enbrel (rheumatoid arthritis) faces biosimilar competition eroding one of its largest products
Horizon acquisition added significant debt and integration execution risk
GLP-1 obesity market competition from Novo Nordisk and Eli Lilly may be difficult to penetrate
Biosimilar competition for Amgen's own biologics from newer entrants

Dividend & Capital Return

Amgen is a consistent dividend grower, having increased its quarterly dividend every year for over a decade, funded by its exceptional cash generation.

I Document Every Trade — Even the Losses

Options record: 1W-8L. Net worth: 100% GSE preferred. Get the unfiltered updates.

Unsubscribe anytime. I respect your inbox more than Congress respects property rights.

Frequently Asked Questions

What does Amgen make?

Amgen makes biologic medicines for serious diseases. Key products include Repatha (cholesterol), Prolia and XGEVA (bone disease), Enbrel (arthritis), Otezla (psoriasis), and Blincyto and Lumakras (cancer). It also has a growing biosimilar portfolio. This is educational content, not financial advice.

Is Amgen working on an obesity drug?

Yes, Amgen is developing MariTide (AMG 133), a monthly injectable GIP/GLP-1 receptor antagonist/agonist for obesity. Early phase trials showed meaningful weight loss, positioning it as a potential entrant in the GLP-1 obesity market dominated by Novo Nordisk and Eli Lilly. This is educational content, not financial advice.

Does Amgen pay a dividend?

Yes, Amgen has grown its quarterly dividend for over a decade. The biotech generates very high operating margins and strong free cash flow that supports consistent dividend growth and buybacks. This is educational content, not financial advice.

What is a biosimilar and why does Amgen make them?

A biosimilar is a near-identical copy of an approved biologic drug after its patent expires, similar to a generic for small-molecule drugs. Amgen makes biosimilars of other companies' reference biologics to capture market share, leveraging its world-class large-molecule manufacturing. This is educational content, not financial advice.

How profitable is Amgen?

Amgen historically generates operating margins of 40%+ and net margins among the highest in biopharma, reflecting its high-value biologics portfolio and efficient manufacturing. The Horizon acquisition added debt and moderately compressed margins near-term. This is educational content, not financial advice.

Related Stocks

MRK

Merck & Co., Inc.

Healthcare

Merck is a global pharmaceutical and animal health company known for Keytruda, the world's best-selling cancer immunotherapy drug. The company has a strong pipeline in oncology, vaccines, and cardiometabolic diseases and operates one of the largest animal health businesses globally.

LLY

Eli Lilly and Company

Healthcare

Eli Lilly is a global pharmaceutical company at the center of the GLP-1 / obesity drug revolution. Mounjaro (tirzepatide) for diabetes and Zepbound for weight loss have made Lilly one of the fastest-growing and most valuable pharmaceutical companies in the world.

GILD

Gilead Sciences, Inc.

Healthcare

Gilead Sciences is a biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis, and COVID-19. Its HIV franchise (Biktarvy, Descovy, Genvoya, Truvada) dominates the global HIV treatment market and generates billions in annual revenue. Gilead's hepatitis C drugs (Harvoni, Sovaldi) effectively cured the disease and transformed the treatment paradigm, though that market has since contracted as the curable population has been treated. Gilead is expanding into oncology through its Kite Pharma (CAR-T cell therapy) platform.

BIIB

Biogen Inc.

Healthcare

Biogen is a biotechnology company specializing in neuroscience, with a legacy portfolio in multiple sclerosis (MS) and expanding into Alzheimer's disease, ALS, and neuropsychiatric disorders. The company's multiple sclerosis drugs (Tecfidera, Tysabri, Avonex, Vumerity) built its revenue base. Biogen attracted significant controversy and attention with Aduhelm and then Leqembi (lecanemab), its Alzheimer's treatments developed in partnership with Eisai. Leqembi received full FDA approval in 2023 and represents Biogen's most significant near-term growth opportunity.

Recommended Resources

Tools & books I actually use and recommend

SeekingAlpha Premium

Quant ratings, earnings transcripts, and the stock analysis community where I published 300+ articles.

Try SeekingAlpha

The Intelligent Investor

Ben Graham's timeless guide to value investing. The book Warren Buffett calls "the best investing book ever written."

View on Amazon

Interactive Brokers

Low commissions, global market access, and professional-grade tools. This is where I hold my positions.

Open an Account

Some links above are affiliate links. I only recommend products I personally use. See my full disclosures.

Keep Exploring

Hub

All Stocks

Browse all 134 stock profiles by sector.

Best Stocks For Beginners

Curated stock picks for new investors by goal.

Financial Glossary

Understand the terms investors use every day.

Stock vs ETF

Individual stocks vs ETFs — which is right for you?

ETF Profiles

Deep dives on 90+ ETFs across every category.

Buying Your First Stock

How to open a brokerage and buy your first share.

Browse All 134 Stock Profiles

Company information is based on publicly available disclosures and widely-known business facts. No specific price, earnings, or real-time market data is included. This is educational content — not investment advice.